Fem Haven Rx publishes health information for women who want to understand what they are taking, and why, before they take it. Everything here is written to one standard: if the evidence does not support a claim, we do not make it, including when the more honest version is the harder one to tell.
Women are used to being talked down to about their own bodies. They are told to expect less, offered reassurance in place of information, and handed content that is either clinically cold or so softened it says nothing at all.
We are trying to sit in neither of those places. Our goal is that you finish one of our articles knowing what a compound has actually been studied for, how strong that evidence really is, and what to raise with a licensed provider before you begin anything.
Sometimes that means telling you the research is thin, or that a study we would love to cite was never done in women at all. We would rather say so than have you find out later.
This is the most important section on this page, and the reason our standards are stricter than a typical health publisher’s.
Every medication referenced on this site is compounded. It is prescribed by a licensed U.S. provider and prepared by a licensed U.S. compounding pharmacy against a valid prescription. Compounded medications are not FDA-approved.
That is not a disclaimer we tuck into a footer. It is a structural fact that changes what we are permitted to write. A publisher covering an FDA-approved product can point to the approval itself as shorthand for evidence. We cannot, and we do not try to. The full evidentiary burden falls on the primary research literature, which is why the sourcing rules further down this page are written the way they are.
It also means we never describe a compounded formulation as equivalent to, a version of, or a substitute for a branded medication. Those comparisons are common in this industry. They are not accurate, and they do not appear here.
There is a gap at the centre of women’s health publishing that most sites write straight past, and we would rather name it.
A great deal of the foundational research on compounds now marketed to women was conducted in male cohorts, or in a single narrow group of women, and then generalised outward. A study run entirely in postmenopausal participants tells you something real — but it does not automatically tell a thirty-four-year-old what to expect. A trial conducted in men tells you even less.
So we state the study population every single time. Not once, buried in a citation, but in the body of the article wherever the finding appears. If the research was not done in women like you, you will read that in the sentence itself.
We also do not treat normal stages of life as problems to be corrected. Menstrual cycles, perimenopause, and menopause are not conditions our content pathologises. They are contexts we write within.
You will see the term intimate wellness throughout our content. That is a deliberate and consistent choice, applied across every article, and it reflects both how we think about this category and the advertising and platform standards that govern how compounded medications may be discussed publicly.
Our writers work from primary research rather than from other people’s articles. Every draft is built against a sourcing brief before a word of copy exists, and every claim in a finished piece must trace back to a specific, named study — not to “studies show” with nothing standing behind it.
Editors check structure, clarity, and whether the article genuinely answers the question a reader arrived with. They can also send a piece back for being technically accurate and practically useless, which happens more often than you might think.
Content covering a prescription compound, a safety profile, a drug interaction, or a contraindication is reviewed by a licensed U.S. clinician before it publishes. The reviewing clinician’s name and credentials appear at the top of the article, beside the writer’s.
Reviewers confirm that the article reflects the current state of the evidence, that safety information is complete rather than selectively presented, and that no benefit has been described more confidently than the underlying research allows.
Every article passes a separate compliance review before publication. This is distinct from clinical review, and it exists because accuracy and compliance are not the same thing — a statement can be scientifically defensible and still be an impermissible claim for a compounded medication.
Compliance review checks language against a fixed rule set covering outcome hedging, disease framing, FDA terminology, dosage disclosure, and required safety disclosures. Nothing publishes without clearing it.
We use AI tools in parts of our research and drafting workflow. You deserve to be told that rather than discover it.
What it does not mean: no article publishes here without a human writer taking responsibility for it, a human editor reviewing it, a licensed clinician reviewing any clinical content within it, and a compliance reviewer clearing it. AI does not choose our sources, does not decide what evidence is strong enough to publish, and does not sign off on safety information. Where we use an AI-generated presenter in video content, that video carries an on-screen disclosure.
Every article closes with a numbered source list carrying the full citation and a direct link, so you can read the research yourself rather than take our summary of it on trust.
Our sourcing rules:
We label evidence strength in the body of the article rather than in a footnote. You should not have to open a citation to learn that a finding came from a petri dish, or from a cohort that looked nothing like you.
Some of the compounds we write about carry contraindications that matter enormously and are easy to underplay. We do not underplay them.
Where a compound is contraindicated in pregnancy, that warning appears at every mention of the compound in the article, not once in an introduction, and never only in a footnote. The same rule applies to compounds that may influence hormone levels, and to anything relevant to a reader with a hormone-sensitive condition or a personal or family history of one.
Where a compound requires contraception during use, or has a long half-life that means it persists in the body after the last dose, our content says so plainly and says why. We would rather an article read as repetitive than have a reader miss a warning because it appeared only once, three screens up.
These are absolute. There is no editorial circumstance in which any of the following appears on this site:
• A percentage or statistic without a specific, named, linked study behind it.
• The phrase “FDA-approved” applied to a compounded medication.
• A cure claim, a guarantee, or the word “proven” attached to an outcome.
• Disease-treatment framing. We write about wellness support, not about treating or curing conditions.
• A normal stage of life described as a disorder to be fixed.
• A timeline for results. No article here will tell you how many weeks something takes, because the research does not support it.
• Findings from research conducted in men presented as though they apply to women.
• A superiority claim against another provider, product, or brand.
• Branded drug equivalence — no compounded formulation described as being “like” or a version of a branded medication.
• Dosage figures in editorial copy. Dosing is a clinical decision made by your provider, not a marketing detail.
• Weight-loss framing or body-image language of any kind.
• A testimonial without the accompanying statement that results are not typical and vary by individual.
• Before-and-after imagery.
• Content written to rank in search rather than to answer a real question.
Published articles are reviewed on a recurring schedule and re-reviewed whenever significant new research emerges on a compound we cover. The most recent review date appears at the top of every article.
Where new evidence weakens something we previously published, we update the article to reflect it. We do not quietly delete the claim and leave the rest of the piece standing. If an article no longer serves readers, we remove it and redirect any links pointing to it.
We get things wrong sometimes. When we do, the article is corrected and sent back through full editorial, clinical, and compliance review before it republishes. Corrections that materially change a safety statement or a benefit claim are noted on the article itself.
If you have found a mistake, please tell us at support@femhavenrx.com. We would far rather hear it from you than not hear it.
Fem Haven Rx is a telehealth service. We facilitate access to the compounded medications we write about. That is a conflict of interest, and we are not going to pretend it is anything else.
What we do about it: our editorial team writes to the evidence, not to the catalogue. A compound with weak human evidence is described as having weak human evidence, whether or not we offer it. Products and protocols are mentioned in an article only where they are directly relevant to what that article is about.
We do not accept payment, product, or any other consideration in exchange for editorial coverage. No third party can buy a mention, a link, or a favourable description in our content. We do not run advertising on this site.
Prescriptions are issued by licensed U.S. providers in the states where we operate: Arizona, Colorado, Florida, Idaho, Iowa, Kansas, Mississippi, Ohio, Oklahoma, Rhode Island, South Carolina, Texas, Vermont, Wisconsin, and Wyoming. Formulations are prepared by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved.
Tell us what is useful, what is not, and what we have missed. Editorial feedback and corrections: hello@femhavenrx.com.
This page is for informational purposes only and does not constitute medical advice. Some programs include compounded medications prepared by a licensed U.S. compounding pharmacy pursuant to a valid prescription from a licensed provider. Compounded medications are not FDA-approved. Always consult a qualified healthcare provider.
Important Notice About Compounded Medications: Some programs offered through Fem Haven Rx include compounded medications prepared by a licensed U.S. compounding pharmacy pursuant to a valid prescription from a licensed provider. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. They are not generic versions of any FDA-approved drug. These statements have not been evaluated by the Food and Drug Administration. Programs are not intended to diagnose, treat, cure, or prevent any disease.
